Melian E B, Spencer C M, Jarvis B
Adis International Inc, Langhorne, Pennsylvania, USA.
Am J Clin Dermatol. 2001;2(2):89-92; discussion 93. doi: 10.2165/00128071-200102020-00005.
Clobetasol propionate foam (clobetasol foam), a new formulation of the superpotent corticosteroid, has anti-inflammatory, antipruritic and vasoconstrictive properties. It was reported that the absorption rate of clobetasol was greater from the foam than from the solution in cadaver skin. In patients with moderate to severe scalp psoriasis, topical application of clobetasol 0.05% foam twice daily for 2 weeks induced significant improvement of all signs and symptoms of the disease compared with placebo. Compared with clobetasol 0.05% solution, clobetasol foam demonstrated greater improvement of scaling after 2 weeks of treatment and after 2 weeks of follow-up. The investigator's global assessment rated 74% of patients in the clobetasol foam group to be clear or almost clear (90 to 100%) of scalp psoriasis compared with 10% of the placebo foam group. Adverse events at the application site of clobetasol 0.05% foam were limited to one case each of dry skin, eczema, and skin hypertrophy. Clobetasol foam 7 g/day for 2 weeks induced reversible suppression of the hypothalamic-pituitary-adrenal axis in 3 out of 13 patients (methodology of assessment not provided).
丙酸氯倍他索泡沫剂（氯倍他索泡沫）是一种超强效皮质类固醇的新剂型，具有抗炎、止痒和血管收缩特性。据报道，在尸体皮肤中，氯倍他索从泡沫剂中的吸收率高于溶液剂。在中度至重度头皮银屑病患者中，与安慰剂相比，每天两次外用0.05%氯倍他索泡沫剂，持续2周，可使该病的所有体征和症状得到显著改善。与0.05%氯倍他索溶液相比，氯倍他索泡沫剂在治疗2周后及随访2周后，鳞屑改善更明显。研究者整体评估显示，氯倍他索泡沫剂组74%的患者头皮银屑病症状清除或几乎清除（90%至100%），而安慰剂泡沫剂组为10%。0.05%氯倍他索泡沫剂用药部位的不良事件仅限于1例干性皮肤、1例湿疹和1例皮肤肥厚。13例患者中有3例在每天使用7g氯倍他索泡沫剂2周后出现下丘脑-垂体-肾上腺轴的可逆性抑制（未提供评估方法）。
